Laurence W. Lytton 13D and 13G filings for Evoke Pharma, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-03-13 1:32 pm Purchase | 2024-02-09 | 13G | Evoke Pharma, Inc. EVOK | Laurence W. Lytton | 71,610 9.990% | 71,610 (New Position) | Filing |